Col. Eli Lilly founded the Indianapolis-based pharmaceutical company in 1876. Eli Lilly employs 20,397 people in the US and 44,074 worldwide. Eli Lilly generated $34.1 billion in revenue in 2023.

Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...

Whilst Pfizer was providing the medicines needed for the Union war effort, a young cavalry commander named Colonel Eli Lilly was serving in their army. A trained pharmaceutical chemist ...

Letters written by Pvt. Joseph Hotz, Union Army solider and great-great grandfather to Columbus resident Tim Hotz, were ...

However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...

Source: InvestingPro Headquartered in Indianapolis, Indiana, Eli Lilly and Company (NYSE:LLY) was created in 1876 by Colonel Eli Lilly, a pharmacist and veteran of the American Civil War.

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Paulo Nunes dos Santos / Bloomberg via Getty Images Eli Lilly will report third-quarter earnings Wednesday morning, with the focus remaining on the production and sales of its popular weight-loss ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing back ...

Dock David Treece is a former licensed investment advisor and member of the FINRA Small Firm Advisory Board. His focus is on breaking down complex financial topics so readers can make informed ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...